Knight Therapeutics (TSE:GUD) Stock Price Down 0.2% – Should You Sell?

Shares of Knight Therapeutics Inc. (TSE:GUDGet Free Report) fell 0.2% on Monday . The stock traded as low as C$5.65 and last traded at C$5.70. 36,840 shares changed hands during trading, a decline of 37% from the average session volume of 58,048 shares. The stock had previously closed at C$5.71.

Wall Street Analysts Forecast Growth

Separately, Raymond James raised Knight Therapeutics to a “moderate buy” rating in a research report on Friday, November 15th.

Read Our Latest Research Report on GUD

Knight Therapeutics Price Performance

The stock has a market cap of C$581.96 million, a price-to-earnings ratio of -28.75, a P/E/G ratio of -1,013.50 and a beta of 0.50. The company has a 50 day simple moving average of C$5.36 and a 200-day simple moving average of C$5.57. The company has a current ratio of 3.41, a quick ratio of 1.79 and a debt-to-equity ratio of 7.62.

Insider Activity at Knight Therapeutics

In related news, Director Samira Sakhia purchased 20,000 shares of the stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of C$5.15 per share, with a total value of C$103,000.00. Also, insider Sime Armoyan bought 90,300 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of C$5.13 per share, with a total value of C$463,672.44. 45.62% of the stock is owned by insiders.

Knight Therapeutics Company Profile

(Get Free Report)

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.

Featured Articles

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.